Table 1. Clinical value of methylated genes in colorectal cancer.

Gene	Authors	Year	Clinical value	Follow-up	Reference
CDH13/FLBN3	Wang Z, et al.	2011	Poor prognosis	Median duration is 44 months (range, 3–60 months)	[114]
p16INK4a	Mitomi H, et al.	2010	Larger size of tumor, frequent recurrence and poor prognosis	Median duration is 79 months (range, 60–123 months)	[115]
PPARG	Pancione M, et al.	2010	Poor prognosis	Average post-operative duration is 59.56 ± 26.5 months	[116]
EphA1	Herath NI, et al.	2009	Poor prognosis	Two years	[117]
DKK1	Rawson JB, et al.	2011	Related to MSI tumors; indicates favorable outcome	NA	[118]
SFRP1	Rawson JB, et al.	2011	Associated with MSI tumors inversely; indicates poor outcome	NA	[118]
GALR2	Kim JC, et al.	2011	Chemosensitive methylation candidates to bevacizumab	NA	[119]
ALX4	Kim JC, et al.	2011	Chemosensitive methylation candidates to cetuximab	NA	[119]
ER	Harder J, et al.	2009	High risk for local recurrence	NA	[120]
CHFR	Brandes JC, et al.	2005	Correlates with the microsatellite instability phenotype	NA	[121]
OSMR	Kim MS, et al.	2009	Highly specific diagnostic biomarker in fecal DNA	NA	[122]
SFRP2	Huang Z, et al.	2007	Detection of CRC and precancerous lesions in stool DNA	NA	[123]
SFRP2	Oberwalder M, et al.	2007	Detection of precancerous lesions of CRC in stool DNA	NA	[124]
DAPK	Mittag F, et al.	2006	Early event in CRC Carcinogenesis	NA	[125]
TFPI2	Glockner SC, et al.	2009	Potential detection marker in stool DNA	NA	[126]
GATA4	Hellebrekers DM, et al.	2009	Potential detection marker in stool DNA	NA	[127]
GATA5	Hellebrekers DM, et al.	2009	Potential marker	NA	[127]
NGX6	Liu M, et al.	2010	Potential marker	NA	[128]
CDH4	Miotto E, et al.	2004	Potential marker	NA	[129]
Sox17	Zhang W, et al.	2008	Potential marker	NA	[31]
p15INK4b	Ishiguro A, et al.	2006	Potential marker	NA	[130]

NA, not available.